<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(8)</volume><submitter>Sivaraj D</submitter><journal>Blood cancer journal</journal><pagination>71</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6068091</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.</pubmed_title><pmcid>PMC6068091</pmcid><pubmed_authors>Gasparetto C</pubmed_authors><pubmed_authors>Long GD</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Garrett AH</pubmed_authors><pubmed_authors>Green MM</pubmed_authors><pubmed_authors>Rizzieri DA</pubmed_authors><pubmed_authors>McIntyre JL</pubmed_authors><pubmed_authors>Sivaraj D</pubmed_authors><pubmed_authors>Chao NJ</pubmed_authors><pubmed_authors>Kang Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.</name><description/><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Jul</publication><modification>2026-04-17T23:22:20.8Z</modification><creation>2025-04-05T18:34:41.606Z</creation></dates><accession>S-EPMC6068091</accession><cross_references><pubmed>30065277</pubmed><doi>10.1038/s41408-018-0104-5</doi></cross_references></HashMap>